CPIXNasdaqPharmaceutical PreparationsFiscal year ends December 31
CUMBERLAND PHARMACEUTICALS INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026
$6.70−0.48 (-6.69%)
Close on Oct 19, 2026
- Market cap
- $100.38M
- P/E (TTM)
- –
- Dividend yield
- –
CUMBERLAND PHARMACEUTICALS INC revenue by segment
By business segment
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Talicia | $2.35M | $1.92M | – | – | $0 | $0 | – | – | – | – | – | – | 1411.7% | – |
| Sancuso | $1.82M | $2.93M | $3.29M | $3.24M | $3.12M | $2.26M | $2.38M | $2.61M | $2.19M | $1.83M | $2.36M | $1.93M | 1091.4% | -41.8% |
| Vibativ | $1.74M | $2.12M | $6.48M | $2.60M | $2.70M | $3.00M | $2.07M | $1.03M | $2.45M | $1.61M | $2.03M | $2.79M | 1044.6% | -35.6% |
| Caldolor | $1.47M | $965.56K | $896.71K | $867.01K | $1.59M | $1.31M | $1.37M | $1.27M | $844.25K | $1.47M | $1.02M | $1.16M | 885.7% | -7.2% |
| Kristalose | $1.06M | $981.48K | $3.12M | $1.18M | $2.75M | $3.48M | $4.38M | $3.63M | $4.11M | $3.20M | $3.67M | $3.89M | 637.7% | -61.5% |
| Other revenue | $221.53K | $168.85K | $184.62K | $306.51K | $492.39K | $3.14M | $216.92K | $624.20K | $213.79K | $275.33K | – | $299.36K | 133.1% | -55.0% |
| Acetadote | $136.66K | $51.98K | $66.67K | $96.60K | $193.54K | $151.65K | $40.21K | $21.37K | $43.40K | $80.20K | $18.69K | $120.05K | 82.1% | -29.4% |
| Acetadote | – | – | – | – | – | – | – | – | – | – | – | $120.05K | – | – |
| Caldolor | – | – | – | – | – | – | – | – | – | – | – | $1.16M | – | – |
| Kristalose | – | – | – | – | – | – | – | – | – | – | – | $3.89M | – | – |
| Other Products | – | – | – | – | – | – | – | – | – | – | – | $299.36K | – | – |
| Omeclamox-Pak | – | – | – | – | – | – | – | – | – | – | – | $23.29K | – | – |
| Vaprisol | – | – | – | – | – | – | – | – | – | – | – | $0 | – | – |
| Vibativ | – | – | – | – | – | – | – | – | – | – | – | $2.79M | – | – |
| Grant | – | – | – | $0 | – | – | – | $300.00K | $0 | $100.00K | – | $100.00K | – | – |
| Redi Trex | – | – | – | – | – | – | – | – | – | – | – | -$122.56K | – | – |
| Sancuso | – | – | – | – | – | – | – | – | – | – | – | $1.93M | – | – |
| Omeclamox-Pak | – | – | – | – | – | – | – | – | – | $8.66K | – | – | – | – |
| RediTrex | – | – | – | – | – | – | – | – | – | $35.56K | – | – | – | – |
| Vaprisol | – | – | – | $0 | $0 | $0 | – | $0 | $0 | $0 | – | – | – | – |
| New Product Development Funding | – | – | – | – | – | – | – | $200.00K | – | – | – | – | – | – |
| CET | – | – | – | $200.00K | $200.00K | – | – | – | – | – | – | – | – | – |
By region
From the segment and revenue-disaggregation notes of Cumberland Pharmaceuticals's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.